Clinical Trial Update: Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a combination of docetaxel, oxaliplatin, and bevacizumab as first-line therapy in non-small cell lung cancer; results were posted after…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• DOCETAXEL (DOCETAXEL)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Sanofi | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-09-16